PT90248B - Metodo para a inibicao da interleucina-1 num mamifero - Google Patents

Metodo para a inibicao da interleucina-1 num mamifero Download PDF

Info

Publication number: PT90248B
Authority: PT; Portugal
Prior art keywords: compos compos; johnson johnson; compound; formula; benzyl
Prior art date: 1988-04-13

Application number

PT90248A

Other languages

English (en)

Portuguese (pt)

Other versions

PT90248A (pt

Inventor

Ivan George Otterness

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-04-13

Filing date

1989-04-11

Publication date

1994-11-30

1989-04-11 Application filed by Pfizer filed Critical Pfizer

1989-11-10 Publication of PT90248A publication Critical patent/PT90248A/pt

1994-11-30 Publication of PT90248B publication Critical patent/PT90248B/pt

Links

238000000034 method Methods 0.000 title claims abstract description 19
230000005764 inhibitory process Effects 0.000 title description 4
150000001875 compounds Chemical class 0.000 claims abstract description 46
102000000589 Interleukin-1 Human genes 0.000 claims abstract description 25
108010002352 Interleukin-1 Proteins 0.000 claims abstract description 25
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 17
150000003839 salts Chemical class 0.000 claims abstract description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
-1 3-substituted-2-oxindole-1-carboxamides Chemical class 0.000 claims abstract description 10
241000124008 Mammalia Species 0.000 claims abstract description 10
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 10
230000015572 biosynthetic process Effects 0.000 claims abstract description 8
125000001544 thienyl group Chemical group 0.000 claims abstract description 6
210000002808 connective tissue Anatomy 0.000 claims abstract description 4
230000004064 dysfunction Effects 0.000 claims abstract description 4
208000030159 metabolic disease Diseases 0.000 claims abstract 2
208000035475 disorder Diseases 0.000 claims description 9
238000011282 treatment Methods 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 6
230000004097 bone metabolism Effects 0.000 claims description 3
230000004060 metabolic process Effects 0.000 claims description 3
208000001132 Osteoporosis Diseases 0.000 claims description 2
230000036039 immunity Effects 0.000 claims description 2
239000003112 inhibitor Substances 0.000 claims description 2
241000219498 Alnus glutinosa Species 0.000 claims 1
241000894006 Bacteria Species 0.000 claims 1
206010020751 Hypersensitivity Diseases 0.000 claims 1
201000004681 Psoriasis Diseases 0.000 claims 1
239000002253 acid Substances 0.000 claims 1
125000000217 alkyl group Chemical group 0.000 claims 1
208000026935 allergic disease Diseases 0.000 claims 1
230000007815 allergy Effects 0.000 claims 1
210000001519 tissue Anatomy 0.000 claims 1
230000001404 mediated effect Effects 0.000 abstract description 6
210000000988 bone and bone Anatomy 0.000 abstract description 3
208000026278 immune system disease Diseases 0.000 abstract description 2
230000002401 inhibitory effect Effects 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 description 16
239000000203 mixture Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
239000006228 supernatant Substances 0.000 description 5
239000000872 buffer Substances 0.000 description 4
239000000499 gel Substances 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
239000002609 medium Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
239000004743 Polypropylene Substances 0.000 description 3
101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 3
229910052783 alkali metal Inorganic materials 0.000 description 3
150000001340 alkali metals Chemical class 0.000 description 3
238000003556 assay Methods 0.000 description 3
239000002585 base Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000008187 granular material Substances 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
229920001155 polypropylene Polymers 0.000 description 3
239000011734 sodium Substances 0.000 description 3
101150035983 str1 gene Proteins 0.000 description 3
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
241000283725 Bos Species 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000000284 extract Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000004044 response Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
241000894007 species Species 0.000 description 2
KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
CPXGGWXJNQSFEP-UHFFFAOYSA-N 2-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazol-5-amine Chemical compound C1CC(N)=NN1C1=CC=CC(C(F)(F)F)=C1 CPXGGWXJNQSFEP-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
OAWAZQITIZDJRB-UHFFFAOYSA-N 2-chloro-2,2-difluoroacetic acid Chemical compound OC(=O)C(F)(F)Cl OAWAZQITIZDJRB-UHFFFAOYSA-N 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
235000008733 Citrus aurantifolia Nutrition 0.000 description 1
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
208000035126 Facies Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101000976075 Homo sapiens Insulin Proteins 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
108010077895 Sarcosine Proteins 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
235000011941 Tilia x europaea Nutrition 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
241000700605 Viruses Species 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
229910000272 alkali metal oxide Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
244000309466 calf Species 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
201000010099 disease Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
229960005293 etodolac Drugs 0.000 description 1
239000003925 fat Substances 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000000945 filler Substances 0.000 description 1
230000004907 flux Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229920000554 ionomer Polymers 0.000 description 1
239000004571 lime Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000007477 logistic regression Methods 0.000 description 1
239000006210 lotion Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
UNBDDZDKBWPHAX-UHFFFAOYSA-N n,n-di(propan-2-yl)formamide Chemical compound CC(C)N(C=O)C(C)C UNBDDZDKBWPHAX-UHFFFAOYSA-N 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
238000009206 nuclear medicine Methods 0.000 description 1
229940100688 oral solution Drugs 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000003650 oxygenase inhibitor Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
229940103406 seequin Drugs 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000010998 test method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
230000035899 viability Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Indole Compounds (AREA)

PT90248A 1988-04-13 1989-04-11 Metodo para a inibicao da interleucina-1 num mamifero PT90248B (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/181,131 US4861794A (en)	1988-04-13	1988-04-13	3-substituted-2-oxindole-1-carboxamides as inhibitors of interleukin-1 biosynthesis

Publications (2)

Publication Number	Publication Date
PT90248A PT90248A (pt)	1989-11-10
PT90248B true PT90248B (pt)	1994-11-30

Family

ID=22663029

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT90248A PT90248B (pt)	1988-04-13	1989-04-11	Metodo para a inibicao da interleucina-1 num mamifero

Country Status (17)

Country	Link
US (1)	US4861794A (da)
EP (1)	EP0337627B1 (da)
JP (1)	JPH01305028A (da)
KR (1)	KR920002327B1 (da)
AT (1)	ATE89724T1 (da)
AU (1)	AU601325B2 (da)
CA (1)	CA1324761C (da)
DE (1)	DE68906706T2 (da)
DK (1)	DK174389A (da)
HU (1)	HU203970B (da)
IE (1)	IE63458B1 (da)
IL (1)	IL89871A (da)
MY (1)	MY103871A (da)
NZ (1)	NZ228711A (da)
PH (1)	PH25884A (da)
PT (1)	PT90248B (da)
ZA (1)	ZA892623B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5300655A (en) *	1989-04-18	1994-04-05	Pfizer Inc.	2-carboxy-thiophene derivatives
US5047554A (en) *	1989-04-18	1991-09-10	Pfizer Inc.	3-substituted-2-oxindole derivatives
IL95880A (en) *	1989-10-13	1995-12-31	Pfizer	Use of 3-Transformed History of 2-Oxindole for the Preparation of Pharmaceuticals for Inhibition of Interlaukio-1 Biosynthesis
US5006547A (en) *	1990-03-19	1991-04-09	Pfizer Inc.	Tenidap as an inhibitor of the release of elastase by neutrophils
US5008283A (en) *	1990-03-19	1991-04-16	Pfizer Inc.	Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase
US5064851A (en) *	1990-07-24	1991-11-12	Pfizer Inc.	3-(1-substituted-pyrazoyl)-2-oxindole derivatives, compositions and use
DE69221794T2 (de) *	1991-01-21	1998-03-19	Shionogi Seiyaku Kk	3-benzyliden-1-carbamoyl-2-pyrrolidon-analoga
US5122534A (en) *	1991-02-08	1992-06-16	Pfizer Inc.	Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides
WO1992016226A1 (en) *	1991-03-19	1992-10-01	Smithkline Beecham Corporation	Il-1 inhibitors
DE4111305C2 (de) *	1991-04-08	1994-12-01	Mack Chem Pharm	Pharmazeutische Zubereitung zur rektalen Applikation, die ein 2-Oxindol-l-carboxamid-derivat enthält
US5298522A (en) *	1993-01-22	1994-03-29	Pfizer Inc.	6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio
US5545656A (en) *	1995-04-05	1996-08-13	Pfizer Inc.	2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4556672A (en) *	1984-03-19	1985-12-03	Pfizer Inc.	3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents
US4569942A (en) *	1984-05-04	1986-02-11	Pfizer Inc.	N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents
US4678802A (en) *	1985-07-09	1987-07-07	Pfizer Inc.	1-acylcarbamoyloxindole-3-carboxamides as antiinflammatory agents
GB8517958D0 (en) *	1985-07-16	1985-08-21	Cellena Cell Eng Ag	Compositions containing melatonin/homologues
WO1987004618A1 (en) *	1986-01-30	1987-08-13	University Of Utah	Treatment of bone loss
US4677132A (en) *	1986-03-12	1987-06-30	American Home Products Corporation	Inhibition of bone resorption by etodolac
UA25898A1 (uk) *	1987-02-02	1999-02-26	Пфайзер Інк.	Спосіб одержаhhя кристалічhої hатрієвої солі 5-хлор-3-(2-теhоїл)-2-оксііhдол-1-карбоксаміду

1988
- 1988-04-13 US US07/181,131 patent/US4861794A/en not_active Expired - Lifetime
1989
- 1989-03-28 DE DE8989303049T patent/DE68906706T2/de not_active Expired - Fee Related
- 1989-03-28 AT AT89303049T patent/ATE89724T1/de not_active IP Right Cessation
- 1989-03-28 EP EP89303049A patent/EP0337627B1/en not_active Expired - Lifetime
- 1989-03-31 PH PH38414A patent/PH25884A/en unknown
- 1989-04-06 IL IL8987189A patent/IL89871A/en not_active IP Right Cessation
- 1989-04-08 MY MYPI89000447A patent/MY103871A/en unknown
- 1989-04-11 PT PT90248A patent/PT90248B/pt not_active IP Right Cessation
- 1989-04-11 ZA ZA892623A patent/ZA892623B/xx unknown
- 1989-04-11 CA CA000596295A patent/CA1324761C/en not_active Expired - Fee Related
- 1989-04-11 JP JP1091706A patent/JPH01305028A/ja active Pending
- 1989-04-12 IE IE117289A patent/IE63458B1/en not_active IP Right Cessation
- 1989-04-12 NZ NZ228711A patent/NZ228711A/en unknown
- 1989-04-12 KR KR1019890004821A patent/KR920002327B1/ko not_active Expired
- 1989-04-12 AU AU32711/89A patent/AU601325B2/en not_active Ceased
- 1989-04-12 DK DK174389A patent/DK174389A/da not_active Application Discontinuation
- 1989-04-12 HU HU891755A patent/HU203970B/hu not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA1324761C (en)	1993-11-30
NZ228711A (en)	1997-02-24
AU601325B2 (en)	1990-09-06
ZA892623B (en)	1990-11-28
DK174389D0 (da)	1989-04-12
PT90248A (pt)	1989-11-10
EP0337627B1 (en)	1993-05-26
AU3271189A (en)	1989-10-19
US4861794A (en)	1989-08-29
HU203970B (en)	1991-11-28
IL89871A (en)	1994-11-11
JPH01305028A (ja)	1989-12-08
EP0337627A2 (en)	1989-10-18
MY103871A (en)	1993-09-30
DE68906706D1 (de)	1993-07-01
DE68906706T2 (de)	1993-09-16
EP0337627A3 (en)	1991-01-02
IE891172L (en)	1989-10-13
HUT52377A (en)	1990-07-28
IE63458B1 (en)	1995-04-19
KR920002327B1 (ko)	1992-03-21
PH25884A (en)	1991-12-02
IL89871A0 (en)	1989-12-15
ATE89724T1 (de)	1993-06-15
KR890015739A (ko)	1989-11-25
DK174389A (da)	1989-10-16

Legal Events

Date

Code

Title

Description

1994-11-30

FG3A

Patent granted, date of granting

Effective date: 19940526

2001-03-30

MM3A

Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20001130

Publication	Publication Date	Title
PT90248B (pt)	1994-11-30	Metodo para a inibicao da interleucina-1 num mamifero
AU2025210803A1 (en)	2025-10-16	Implantable devices for cell therapy and related methods
ES2227555T3 (es)	2005-04-01	Metodo para la inhibicion de la metastasis cancerosa mediante la administracion oral de pectina citrica soluble modificada.
McIsaac et al.	1959	Comparison of the effects of inhibition of external, internal and total acetylcholinesterase upon ganglionic transmission
AU2004273610B2 (en)	2010-07-01	Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
ES2778053T3 (es)	2020-08-07	Composiciones para modular la actividad de la citocina gamma-c
ES2949273T3 (es)	2023-09-27	Inhibidores de transglutaminasas
BR112021002250A2 (pt)	2021-07-20	compostos de ligação ao receptor de il-2
SK70693A3 (en)	1994-02-02	Pharmaceutical composition based on cyclic adhesion inhibitors of animal cells
EA200400488A1 (ru)	2004-10-28	Бензамид и гетероариламид в качестве антагонистов рецептора p2x
PL200919B1 (pl)	2009-02-27	Zastosowanie kompozycji czynnika hamującego angiogenezę i czynnika przeciwnowotworowego, kompozycja terapeutyczna do leczenia nowotworów i zestaw do traktowania komórki nowotworowej
ES2331102T3 (es)	2009-12-21	Compuestos con propiedades de liberacion de la hormona del crecimiento.
RU2012126076A (ru)	2013-12-27	Липопептидные композиции и родственные способы
PT2263694E (pt)	2013-08-27	Agente antitumoral compreendendo o inibidor da histona desacetilase fk228 e o inibidor da topoisomerase ii, doxorrubicina
PT813423E (pt)	2002-11-29	Composicao para inibir osteolise e metastese
PT95451A (pt)	1991-05-22	Processo para a preparacao de composicoes aquosas estabilizadas de pequenos peptidos
EP1082963A1 (en)	2001-03-14	Remedies for joint diseases bound to hyaluronic acid
ES2745802T3 (es)	2020-03-03	Péptido para suprimir la diferenciación de osteoclastos y uso del mismo
EP3773597A1 (en)	2021-02-17	Phenothiazine derivatives and uses thereof
BRPI0012675B1 (pt)	2001-02-01	Uso de anticorpos contra il-18 e il-18bp, assim como uso de um vetor de expressão codificando para ditos anticorpos contra il-18 e il-18bp
ES2255829B1 (es)	2007-08-16	Nuevo uso de sales de glucosamina.
NZ549989A (en)	2008-10-31	New therapeutic use for a group of sulphated polysaccharides
HU218947B (hu)	2001-01-29	Metabolikus csontbetegség kezelésére szolgáló humán Il-1R proteint tartalmazó gyógyszerkészítmények
ITMI20122145A1 (it)	2014-06-15	Composizioni per uso orale contenenti idrolizzati di collagene, di elastina e vitamina c favorenti la deposizione di matrice extra-cellulare
Bazhenova et al.	2005	Reactive thrombocytosis associated with a pheochromocytoma